Tirzepatide drug classification: understanding what kind of medicine this is

You've seen 'dual agonist' on the box, here's what that actually means

Imagine you've just picked up a Mounjaro KwikPen and you're reading the leaflet. The phrase glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist appears early on, and it's a mouthful. Strip it back and the meaning is straightforward: tirzepatide is a synthetic peptide designed to mimic two hormones your gut already produces after eating. Both GIP and GLP-1 signal to the brain and pancreas that food has arrived, they increase feelings of fullness, slow the rate at which the stomach empties, and help regulate blood sugar. If you're curious about what class of medication Mounjaro belongs to, that starts with understanding how both receptor types are activated at once.

That dual-receptor action is what sets tirzepatide's drug classification apart from earlier GLP-1 medicines such as semaglutide, which only activates the GLP-1 pathway. Whether that extra GIP action is the main driver of the larger average weight reductions seen in trials, or whether the two pathways simply reinforce each other, is still an active area of research. What the trials established is the outcome: in SURMOUNT-1, thousands of adults without diabetes lost an average of around 20–21% of their body weight at the 15mg dose over 72 weeks, as published in the New England Journal of Medicine. The classification explains the mechanism; the trial evidence quantifies the result.

A question our prescribers hear most weeks is whether tirzepatide is essentially the same as Ozempic or Wegovy. It is not. Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist only. Tirzepatide's classification as a dual agonist is genuinely distinct, different molecular structure, different receptor profile, different drug class.

Classification, prescription status and the Black Triangle

Tirzepatide's formal regulatory status in the UK is a Prescription-Only Medicine, authorised by the MHRA. That classification has a direct practical consequence: it cannot be legally supplied to you without a prescription generated by a qualified prescriber following a clinical review. This is not a technicality, it reflects the fact that the medicine affects appetite, metabolism, gastric emptying and blood sugar, and those effects need to be assessed against your personal health picture before treatment begins.

The Black Triangle (▼) marking you will see on Mounjaro packaging places it in a category of medicines under enhanced MHRA surveillance. This does not mean the medicine is unsafe; it means it was recently authorised and the regulator wants manufacturers to report safety data more frequently than for older, established drugs. Many recently licensed medicines carry this designation temporarily. The Mounjaro drug class page explores what the regulatory status means in practice for people starting treatment.

Tirzepatide holds two licensed indications in the UK: weight management in adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition), and the management of type 2 diabetes. The classification as a dual GIP and GLP-1 receptor agonist applies to both. The licensed dose range runs from 2.5mg up to 15mg, with the starting dose set deliberately low to allow the body to adjust, particularly important given the gastrointestinal side effects that can accompany this class of medicine. For the full prescribing detail, the BNF entry for tirzepatide is the reference clinicians use.

Where tirzepatide sits among weight-loss medicines available in the UK

The landscape of licensed weight-loss medicines in the UK now spans several drug classes. Orlistat is a lipase inhibitor, it works in the gut to block fat absorption, with no hormonal mechanism at all. Semaglutide (Wegovy) is a GLP-1 receptor agonist, single-pathway. Tirzepatide sits in its own sub-class as the only dual GIP and GLP-1 agonist currently licensed for weight management in the UK. That classification matters when comparing expected outcomes and side-effect profiles, and it is one reason clinicians and patients researching tirzepatide find the head-to-head data interesting.

From a drug-testing perspective, tirzepatide is detectable in blood and urine and can affect standard laboratory values, particularly fasting glucose, insulin and liver enzymes. If you are subject to occupational health screening or any other formal drug testing, that is worth discussing with your prescriber before you start. The tirzepatide and drug testing page covers that question in detail.

For most people reading this page, the classification question is really a stepping stone to a more practical one: is this medicine suitable for me? That is a clinical assessment, not a classification exercise. BMI alone does not determine suitability, a prescriber weighs your full health history, current medicines, and any contraindications. You can read more about the tirzepatide overview or explore weight-loss treatment options more broadly before deciding whether to take the next step.

What this classification means for safety and monitoring

Understanding the drug class also helps frame what to watch for. As a GIP and GLP-1 receptor agonist, tirzepatide slows gastric emptying, which is why nausea, loose stools, constipation and indigestion are the most commonly reported side effects, usually most noticeable in the first weeks of a new dose and settling as the body adapts. These are class effects shared with other GLP-1 medicines, not unique to tirzepatide specifically.

Two safety considerations deserve particular attention. First, tirzepatide can reduce the absorption of oral medicines taken at the same time, including oral contraceptive pills. Women using the pill should discuss adding a barrier method for the first four weeks of treatment and for four weeks after each dose increase. Second, the MHRA has highlighted acute pancreatitis as an infrequent but serious risk across the GLP-1 class: severe, persistent abdominal pain that radiates to the back needs prompt medical attention. These risks are built into the prescribing process, which is precisely why clinical assessment happens before a prescription is issued, and why a prescriber reviews every repeat order rather than simply renewing it automatically.

If you want to understand your own eligibility and whether tirzepatide's classification, licence and risk profile fit your situation, check your eligibility with our prescribers, the consultation is free, and a GPhC-registered Independent Prescriber reviews every submission the same day.